TIP_link_300x300.jpg
Liquid Biopsy Market Size worth $8.12 Bn Globally by 2027 at 9.9% CAGR Says, The Insight Partners
July 26, 2022 07:34 ET | The Insight Partners
New York, July 26, 2022 (GLOBE NEWSWIRE) -- The Insight Partners published latest research study on “Liquid Biopsy Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Product &...
FBI LOGO TM.png
Exosomes Market Size [2022-2029] | Industry Trends, Share, Growth, SWOT Analysis, Market Drivers, Restraints, Opportunities, And Key Developments
July 20, 2022 05:12 ET | Fortune Business Insights
Pune, India, July 20, 2022 (GLOBE NEWSWIRE) -- The global “Exosomes Market Size” is expected to gain momentum owing to the rising prevalence of cancer during the forecast period. This information is...
Cells for Cells logo.png
CELLS for CELLS treats the first-ever patient with an exosome-produced therapy for osteoarthritis
July 18, 2022 15:54 ET | Cells for Cells
SAN FRANCISCO, July 18, 2022 (GLOBE NEWSWIRE) -- Cells for Cells ("C4C"), a clinical-stage biotech pioneering allogeneic stem cell and stem-cells-derived therapeutics for high-impact chronic...
ARC logo.png
Global Exosomes Market Surpass USD 2,200 Million by 2030 - Exclusive Report By Acumen Research And Consulting
June 13, 2022 14:06 ET | Acumen Research and Consulting
SEATTLE, June 13, 2022 (GLOBE NEWSWIRE) -- The global exosomes market size is estimated to grow a CAGR above 34% over the forecast timeframe and reach a market value of around USD 2,273 million by...
Aesthetic Management Partners Announces Exclusive Distribution Agreement With Estar Medical
May 23, 2022 08:00 ET | Aesthetic Management Partners
CORDOVA, Tenn., May 23, 2022 (GLOBE NEWSWIRE) -- Estar Medical, the maker of Eclipse PRP® and Tropocells®, has signed an exclusive long-term marketing and distribution agreement with Aesthetic...
3787276_Codiak_Logo_White_CMYK.jpg
Codiak BioSciences Reports First Quarter 2022 Financial Results and Operational Progress
May 05, 2022 16:01 ET | Codiak BioSciences, Inc.
– Codiak to provide data from ongoing exoSTING™ and exoIL-12™ clinical trials in late 1H 2022 – – Anticipate first patients dosed in exoASO™-STAT6 Phase 1 clinical trial in 1H 2022 – – Data from...
Codiak Appoints David Mauro, M.D., Ph.D., as Chief Medical Officer
May 02, 2022 09:00 ET | Codiak BioSciences, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a clinical-stage biopharmaceutical company pioneering the development of exosome-based therapeutics as a...
3787276_Codiak_Logo_White_CMYK.jpg
Codiak Presents New Preclinical Data Supporting Development of a Broadly Protective Pan Beta-Coronavirus Vaccine
April 20, 2022 16:40 ET | Codiak BioSciences, Inc.
– Engineered exosome vaccine construct generated durable, comprehensive immunity in vivo – CAMBRIDGE, Mass., April 20, 2022 (GLOBE NEWSWIRE) -- Codiak BioSciences, Inc. (Nasdaq: CDAK), a...
3787276_Codiak_Logo_White_CMYK.jpg
Codiak’s exoASO™-C/EBPβ Demonstrates Significant Systemic Anti-Tumor Activity via Targeting Immune-Suppressive Myeloid Cells
April 08, 2022 13:00 ET | Codiak BioSciences, Inc.
– New preclinical data presented at AACR Annual Meeting 2022 – – Intravenous exosome candidate engineered for tropism precisely targets transcription factors in myeloid cell subpopulations – –...
3787276_Codiak_Logo_White_CMYK.jpg
Codiak BioSciences Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Operational Progress
March 10, 2022 16:01 ET | Codiak BioSciences, Inc.
– Reported positive initial data from exoSTING™ clinical trial; on track to provide data from all dose escalation cohorts in late 1H 2022 – – Investigational New Drug (IND) application cleared for...